We provide patients with an all-important step-by-step guide and support needed

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

BACKGROUND Patients with advanced biliary tract cancer have a poor prognosis, and first-line standard of care (gemcitabine plus cisplatin) has remained unchanged for more than 10 years. The TOPAZ-1 trial evaluated durvalumab plus chemotherapy for patients with advanced biliary tract cancer…. Continue to publication

About Author
Steve Holmes

Gold Coast, Australia
Kiwi-born Waikanae, New Zealand
CEO at Cholangiocarcinoma Foundation Australia & ( NZ)
Founder of The Main Beach Foundation – Putting Community Responsibility back into Cancer

Your biggest RISK when responding to a cancer diagnosis is not knowing what you do not know. Your biggest advantage is to begin learning from someone who does. Providing “Targeted Health Literacy”

By Steve|2022-12-02T14:34:04+13:00December 2nd, 2022|Publication|0 Comments

0 0 votes

Article Rating

0 Comments

Inline Feedbacks

View all comments

Our Mission and Purpose

Utilisation and Delivery

Better Utilisation and Delivery of the most up-to-date treatments and processes available

Equip and Empower

Better Equip & Empower a patients capacity to respond to a cholangiocarcinoma diagnosis

Aligning the effort

Better alignment of the patient’s supporters and professionals to maximise the most effective synchronised effort possible.

Overarching Mission

CCF New Zealand’s overarching mission is to support the development of effective curative treatments for Cholangiocarcinoma Patients.

Join our updates

CCA Patient Toolkit

Newly Diagnosed Patients

You do not know what you do not know.

The toolkit helps you know what you must know in the order you must know it.

Equip and Empower

The Cancer Toolkit is a step-by-step guide to navigating a cholangiocarcinoma diagnosis. It better equips and empowers your capacity to respond more effectively.

Same Page

The toolkit will keep you on track, it is also designed to align and synchronise your supporters and medical team, to ensure the most cohesive responsive effort possible. This is an essential x-factor ingredient in combating cancer.

CCA Patient Toolkit

We would like to thank Cholangiocarcinoma.org (USA) for their unwavering support of CCF New Zealand.

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

Share this Story

Our Mission and Purpose

Utilisation and Delivery

Equip and Empower

Aligning the effort

Overarching Mission

CCA Patient Toolkit

Newly Diagnosed Patients

You do not know what you do not know.

Equip and Empower

Same Page

Copyright 2022| All Rights Reserved | CCF New Zealand